Literature DB >> 24197890

Characterization of rough and smooth morphotypes of Mycobacterium abscessus isolates from clinical specimens.

Kai Rüger1, Annegret Hampel, Sandra Billig, Nadine Rücker, Sebastian Suerbaum, Franz-Christoph Bange.   

Abstract

Mycobacterium abscessus, which consists of the two subspecies M. abscessus subspecies abscessus and M. abscessus subspecies bolletii, can produce rough or smooth colony morphologies. Here we analyzed 50 M. abscessus isolates cultured from the respiratory specimens of 34 patients, 28 (82%) of whom had cystic fibrosis (CF), with respect to their colony morphologies and antibiotic susceptibilities. The overall proportions of occurrences of the two morphotypes were similar, with specimens from 50% of the patients showing a rough and 38% showing a smooth morphotype. A total of 12% of the specimens from the patients showed both morphotypes simultaneously. At the subspecies level, the proportions of rough and smooth morphotypes differed substantially; 88% of rough morphotypes belonged to M. abscessus subspecies abscessus, and 85% of smooth morphotypes belonged M. abscessus subspecies bolletii. Inducible clarithromycin resistance due to the Erm(41) methylase, as well as high-level resistance to clarithromycin due to mutations within the rrl gene, occurred independently of the morphotype. The MIC50s of amikacin and cefoxitin were identical for the two morphotypes, whereas the MIC50s of tigecycline were 0.25 μg/ml for the rough morphotype and 2.0 μg/ml for the smooth morphotype. Our results show that the smooth morphotype was more dominant in respiratory specimens from CF patients than previously thought. With respect to resistance, colony morphology did not affect the susceptibility of Mycobacterium abscessus to the first-line antibiotics clarithromycin, amikacin, and cefoxitin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24197890      PMCID: PMC3911423          DOI: 10.1128/JCM.01249-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  Acute respiratory failure involving an R variant of Mycobacterium abscessus.

Authors:  Emilie Catherinot; Anne-Laure Roux; Edouard Macheras; Dominique Hubert; Moussa Matmar; Luc Dannhoffer; Thierry Chinet; Philippe Morand; Claire Poyart; Beate Heym; Martin Rottman; Jean-Louis Gaillard; Jean-Louis Herrmann
Journal:  J Clin Microbiol       Date:  2008-11-19       Impact factor: 5.948

2.  Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection.

Authors:  T F Byrd; C R Lyons
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype.

Authors:  Susan T Howard; Elizabeth Rhoades; Judith Recht; Xiuhua Pang; Anny Alsup; Roberto Kolter; C Rick Lyons; Thomas F Byrd
Journal:  Microbiology       Date:  2006-06       Impact factor: 2.777

4.  Molecular epidemiology of Mycobacterium abscessus, with focus on cystic fibrosis.

Authors:  Bodil E Jönsson; Marita Gilljam; Anders Lindblad; Malin Ridell; Agnes E Wold; Christina Welinder-Olsson
Journal:  J Clin Microbiol       Date:  2007-03-21       Impact factor: 5.948

5.  Amoebal coculture of "Mycobacterium massiliense" sp. nov. from the sputum of a patient with hemoptoic pneumonia.

Authors:  Toïdi Adékambi; Martine Reynaud-Gaubert; Gilbert Greub; Marie-José Gevaudan; Bernard La Scola; Didier Raoult; Michel Drancourt
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

6.  rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov.

Authors:  Toïdi Adékambi; Pierre Berger; Didier Raoult; Michel Drancourt
Journal:  Int J Syst Evol Microbiol       Date:  2006-01       Impact factor: 2.747

7.  Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus.

Authors:  R J Wallace; A Meier; B A Brown; Y Zhang; P Sander; G O Onyi; E C Böttger
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

8.  A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.

Authors:  Kevin A Nash; Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

9.  [Nontuberculous mycobacterial infection in patients with cystic fibrosis: a multicenter prevalence study].

Authors:  Rosa M Girón; Luis Máiz; Isabel Barrio; M Teresa Martínez; Antonio Salcedo; Concepción Prados
Journal:  Arch Bronconeumol       Date:  2008-12       Impact factor: 4.872

10.  Proportions of Mycobacterium massiliense and Mycobacterium bolletii strains among Korean Mycobacterium chelonae-Mycobacterium abscessus group isolates.

Authors:  Hee-Youn Kim; Yoonwon Kook; Yeo-Jun Yun; Chan Geun Park; Nam Yong Lee; Tae Sun Shim; Bum-Joon Kim; Yoon-Hoh Kook
Journal:  J Clin Microbiol       Date:  2008-08-27       Impact factor: 5.948

View more
  24 in total

1.  Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies.

Authors:  Faiza Mougari; Feriel Bouziane; Flora Crockett; Rachid Nessar; Françoise Chau; Nicolas Veziris; Guillaume Sapriel; Laurent Raskine; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

2.  In Vitro Evaluation of Povidone-Iodine and Chlorhexidine against Outbreak and Nonoutbreak Strains of Mycobacterium abscessus Using Standard Quantitative Suspension and Carrier Testing.

Authors:  Aristine Cheng; Hsin-Yun Sun; Yi-Tzu Tsai; Un-In Wu; Yu-Chung Chuang; Jann-Tay Wang; Wang-Huei Sheng; Po-Ren Hsueh; Yee-Chun Chen; Shan-Chwen Chang
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Interference with Pseudomonas aeruginosa Quorum Sensing and Virulence by the Mycobacterial Pseudomonas Quinolone Signal Dioxygenase AqdC in Combination with the N-Acylhomoserine Lactone Lactonase QsdA.

Authors:  Franziska S Birmes; Ruth Säring; Miriam C Hauke; Niklas H Ritzmann; Steffen L Drees; Jens Daniel; Janina Treffon; Eva Liebau; Barbara C Kahl; Susanne Fetzner
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

Review 4.  Mucosal Immunity in Cystic Fibrosis.

Authors:  Christine M Bojanowski; Shiping Lu; Jay K Kolls
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.426

5.  High-Throughput Screening Identifies Synthetic Peptides with Antibacterial Activity against Mycobacterium abscessus and Serum Stability.

Authors:  Natalie Iannuzo; Yannik A Haller; Michelle McBride; Sabrina Mehari; John C Lainson; Chris W Diehnelt; Shelley E Haydel
Journal:  ACS Omega       Date:  2022-06-27

6.  GenoType NTM-DR for Identifying Mycobacterium abscessus Subspecies and Determining Molecular Resistance.

Authors:  Jan Kehrmann; Nermin Kurt; Kai Rueger; Franz-Christoph Bange; Jan Buer
Journal:  J Clin Microbiol       Date:  2016-03-30       Impact factor: 5.948

7.  The many lives of nontuberculous mycobacteria.

Authors:  Tiffany A Claeys; Richard T Robinson
Journal:  J Bacteriol       Date:  2018-02-26       Impact factor: 3.490

8.  Survival of pathogenic Mycobacterium abscessus subsp. massiliense in Acanthamoeba castellanii.

Authors:  Joas L da Silva; Jan Nguyen; Kevin P Fennelly; Adrian M Zelazny; Kenneth N Olivier
Journal:  Res Microbiol       Date:  2017-10-19       Impact factor: 3.992

9.  Mycobacteriophages as Genomic Engineers and Anti-infective Weapons.

Authors:  Mark R Sullivan; Eric J Rubin; Charles L Dulberger
Journal:  mBio       Date:  2021-05-18       Impact factor: 7.867

10.  Mycobacterium abscessus morphotype comparison in a murine model.

Authors:  Lindsay J Caverly; Silvia M Caceres; Cori Fratelli; Carrie Happoldt; Kelley M Kidwell; Kenneth C Malcolm; Jerry A Nick; David P Nichols
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.